Selpercatinib demonstrated a highly statistically significant and clinically meaningful improvement in reducing the risk of disease recurrence or death Results from the LIBRETTO-432 trial build on ...
7don MSN
Eli Lilly's Jaypirca builds case with fourth positive phase 3 trial in blood cancer patients
Eli Lilly and Co. LLY shares were little changed in Monday’s premarket session. The U.S. drug giant shared results from the ...
Eli Lilly’s oral targeted cancer therapy, Retevmo, has shown benefit as an adjunctive therapy in a Phase III trial in patients with early-stage (II-IIIA) rearranged during transfection (RET) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results